pISSN 1226-6051
eISSN 2508-786X

Table. 4.

Table. 4.

Outcomes of users of dabigatran vs. warfarin

Dabigatran user (n=721) Matched warfarin user (n=721) Hazard Ratio(95% CI)


Events(%) Person-years(PYs) IR/100PYs Events(%) Person-years(PYs) IR/100PYs
MACCE 11(1.53) 245.21 4.49 17(2.36) 450.16 3.78 1.00(0.47-2.15)
Ischemic stroke/systemic embolism 2(0.28) 246.81 0.81 3(0.42) 456.52 0.66 1.04(0.15-7.38)
Myocardial infarction 9(1.25) 245.83 3.66 10(1.39) 453.99 2.20 1.42(0.60-3.36)
Cardiac death 1(0.14) 247.28 0.40 4(0.55) 456.04 0.88 0.35(0.04-3.15)
Bleeding 9(1.25) 245.12 3.67 29(4.02) 444.99 6.52 0.47(0.22-1.03)
Intracranial bleeding 0(0) 247.44 0 6(0.83) 456.63 1.32 NA
Gastrointestinal bleeding 9(1.25) 245.12 3.67 24(3.33) 447.28 5.37 0.58(0.26-1.30)

MACCE, major adverse cerebro-cardiovascular events; IR, incidence rate; PY, person-years; CI, confidence interval

Korean J Clin Pharm 2022;32:37-46 https://doi.org/10.24304/kjcp.2022.32.1.37
© 2022 Korean J Clin Pharm